Target Validation Information
TTD ID	T96627
Target Name	C-X-C motif chemokine 2 (CXCL2)
Type of Target	Clinical trial
Action against Disease Model	Laquinamod	Drug Info	Experimental evidence to date, derived mostly from animal models of multiple sclerosis, suggests that laquinimod may mediate its effects via modulating pro-inflammatory immune responses and interfering with cell trafficking, as well as potentially acting directly in the central nervous system to limit demyelination and axonal injury.	[1]
References
REF 1	Laquinimod in multiple sclerosis. Clin Immunol. 2012 Jan;142(1):38-43.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.